N-hydroxy-5-(4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)-1H-indazol-1-yl)pentanamide | 1235447-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: N-hydroxy-5-(4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)-1H-indazol-1-yl)pentanamide
• 英文别名: N-hydroxy-5-(4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothien[3,2-d]pyrimidin-2-yl)-1H-indazol-1-yl)pentanamide；N-hydroxy-5-(4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothien-[3,2-d]pyrimidin-2-yl)-1H-indazol-1-yl)pentanamide；N-hydroxy-5-[4-[6-[(4-methylsulfonylpiperazin-1-yl)methyl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl]indazol-1-yl]pentanamide
• CAS: 1235447-87-6
• 化学式: C₂₈H₃₆N₈O₅S₂
• 分子量: 628.776
• InChiKey: PZCFAXKRBOEWTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  43
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  183
• 氢给体数：
  2
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  ethyl 5-(4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)-1H-indazole-1-yl)pentanoate 在 盐酸羟胺 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 反应 0.25h， 以58%的产率得到N-hydroxy-5-(4-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinothieno[3,2-d]pyrimidin-2-yl)-1H-indazol-1-yl)pentanamide
  参考文献：
  名称：

  TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

  摘要：

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：（1）识别患有与K-ras突变相关的癌症的受试者；和（2）向受试者施用（i）PI3激酶抑制剂和（ii）HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以联合治疗有效的剂量进行施用。

  公开号：

  US20130102595A1

文献信息

• [EN] TREATMENT OF CANCERS HAVING K-RAS MUTATIONS<br/>[FR] TRAITEMENT DE CANCERS PRÉSENTANT DES MUTATIONS K-RAS
  申请人：CURIS INC

  公开号：WO2011130628A1

  公开（公告）日：2011-10-20

  The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：(1) 鉴定患有与K-ras突变相关的癌症的受试者；和 (2) 给予该受试者 (i) PI3激酶抑制剂和 (ii) HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以治疗有效的剂量一起给予。
• 亜鉛結合部分を有するホスホイノシチド３−キナーゼインヒビター
  申请人：キュリス,インコーポレイテッド

  公开号：JP2015187145A

  公开（公告）日：2015-10-29

  PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety.SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; Gis optionally substituted N or the like; Rand Rare each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Rand Rtogether with the nitrogen atom coupled to them are morpholino or the like; Gis an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.)

  要解决的问题：提供具有锌结合基团的磷脂酰肌醇3-激酶抑制剂。解决方案：提供了一个由下图中的式（I）表示的化合物。（X为S、O或类似物；Y为CH、N或类似物；G是可选地取代的N或类似物；R和R分别独立地为H或类似物；C为取代的杂环或类似物；B为线性烷基或类似物；R和R与它们结合的氮原子一起是吗啡基或类似物；G是吲唑环或类似物；q、r和s独立地从0到1，但至少其中之一为1；t从0到1；n从0到4；p从0到2。）
• PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY
  申请人：Cai Xiong

  公开号：US20100222343A1

  公开（公告）日：2010-09-02

  The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

  本实用新型涉及具有基于锌结合基团的脱氮嘌呤、噻吩嘧啶和呋喃嘧啶衍生物及其在治疗与磷脂酰肌醇3-激酶相关的疾病和疾病方面的应用，例如癌症。本实用新型进一步涉及与组蛋白去乙酰化酶相关的疾病和同时涉及组蛋白去乙酰化酶和磷脂酰肌醇3-激酶相关的疾病的治疗。
• Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
  申请人：Curis, Inc.

  公开号：US10336770B2

  公开（公告）日：2019-07-02

  The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

  本申请涉及去氮嘌呤类、噻吩嘧啶类和呋喃嘧啶类与锌结合基的衍生物，以及它们在治疗磷酸肌酸 3- 激酶相关疾病和紊乱（如癌症）中的用途。本申请还涉及组蛋白去乙酰化酶相关疾病以及组蛋白去乙酰化酶和磷酸肌酸 3-激酶相关疾病的治疗。
• US8367663B2
  申请人：——

  公开号：US8367663B2

  公开（公告）日：2013-02-05